ResearchSpeak & #ThinkHand: ECTRIMS highlight sustained improvement in SPMS Wow who would have thought you would get improved function in advanced SPMS? #ThinkHand #ECTRIMS2016 #ResearchSpeak #MSBlog "The poster below is one of my ECTRIMS highlights. It has made me think differently about MS in particular about the mechanisms behind the improvement in neurological function. In short if the natalizumab in SPMS trial (ASCEND study) had been designed with the primary outcome being sustained…
The multiple sclerosis drug Tysabri (natalizumab) increases the risk of a fatal brain virus ten-fold. Progressive multifocal leukoencephalopathy (PML) is a rare disease that attacks the brain’s white matter—but it becomes more common when the immune system is compromised, as can happen when people take immunosuppressive drugs, say researchers.
Tysabri Protects Against Relapse in Multiple Sclerosis, According To Study
Tysabri Protects Against Relapse in Multiple Sclerosis, patients are a a high risk for developing PML. Many multiple sclerosis patients are also treated with natalizumab, which is an monoclonal antibody immunosuppressive medication. Putting the two together, some multiple sclerosis patients see a risk for extended use of Tysabri and desire a different treatment. “It’s difficult for patients to make decisions, In his experience, when the risk of PML for multiple scleros